Switching between oral and injectable pre-exposure prophylaxis (PrEP) regimens in the United States: an investigation of reasons for switching in the real world
5th HIVR4P
L. Tao*1,, J. Yang1,, D. Mezzio1,, C. Nguyen1,, W. Zachry1,, J. Gruber1,.
1Gilead Sciences, Inc., Foster City, California
